.svg)
Male Hypogonadism and the Brain–Testis Axis on a Lab Report
Male hypogonadism biomarkers are blood signals that map how well the brain–testis system is supplying and delivering male hormones. They help confirm whether androgen activity is adequate and show where any slowdown is occurring—at the testes themselves or higher up in the control center. Core markers include testosterone (the main androgen made by testicular Leydig cells), free testosterone (the unbound, bioactive fraction), and sex hormone–binding globulin or SHBG (the carrier protein that sets hormone availability). Pituitary messengers—luteinizing hormone, LH (the driver of Leydig cells), and follicle‑stimulating hormone, FSH (the driver of Sertoli cells and sperm development)—reveal the brain’s stimulation of the testes. Prolactin (a pituitary hormone) and estradiol (an aromatized form of testosterone) show feedback forces that can dampen this axis. Inhibin B (a Sertoli cell product) reflects spermatogenic activity. Together, these biomarkers provide a coherent picture of androgen supply, tissue‑ready hormone, pituitary drive, and sperm‑support function, enabling precise diagnosis, fertility assessment, and targeted treatment monitoring in male hypogonadism.
Why Confirming Low T Matters Before Acting
Male hypogonadism testing looks at the brain–testis axis—total testosterone, free and bioavailable testosterone, and the pituitary signals LH and FSH. These markers reflect how well your body maintains vitality across systems: sexual function and fertility, muscle and bone building, mood and cognition, red blood cell production, and metabolic health.In healthy adult men, morning total testosterone typically sits in the mid‑to‑upper portion of a lab’s reference range. Free testosterone is the small active fraction (about 1–3% of total), and bioavailable testosterone (free plus albumin‑bound) is roughly a third to a half of total; both often track best with symptoms and tend to feel optimal in the middle of their ranges. LH and FSH usually rest in the low‑to‑mid normal range when feedback is intact. With age, values drift lower; during puberty they rise into adult ranges.When testosterone is low with high LH/FSH, the testes are underperforming (primary hypogonadism); when testosterone is low with low or inappropriately normal LH/FSH, the brain signals are weak (secondary hypogonadism). Effects can include low libido, fewer morning erections, erectile difficulties, fatigue, low mood, reduced muscle and strength, increased visceral fat, anemia, decreased bone density and fracture risk, and infertility. Teen boys may show delayed puberty and slow growth.Big picture: these labs connect reproductive hormones to bone, blood, brain, and metabolism. Persistently low androgen signaling is linked to osteoporosis, anemia, adverse body composition, insulin resistance, depressive symptoms, and reduced quality of life, making accurate blood testing central to diagnosis and long‑term risk assessment.
What Hormone Testing Settles — and What It Leaves Open
Male hypogonadism blood testing provides a window into the hormonal systems that drive energy, metabolism, cardiovascular health, cognition, reproduction, and immune function. At Superpower, we measure Testosterone, Free Testosterone (Free T), Bioavailable Testosterone, Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH) to assess the integrity of the male reproductive axis and its broader impact on whole-body health.Testosterone is the primary male sex hormone, essential for muscle mass, bone strength, mood, and sexual function. Free Testosterone refers to the fraction not bound to proteins, making it immediately available to tissues. Bioavailable Testosterone includes both free and loosely bound forms, representing the hormone’s true physiological activity. LH and FSH are pituitary hormones that regulate testicular function—LH stimulates testosterone production, while FSH supports sperm development.Together, these biomarkers reveal how well the hypothalamic-pituitary-gonadal (HPG) axis is functioning. Healthy levels and relationships among Testosterone, Free T, and Bioavailable T indicate robust androgen signaling, supporting stable mood, metabolism, and reproductive capacity. LH and FSH help distinguish between primary (testicular) and secondary (pituitary or hypothalamic) causes of hypogonadism, clarifying where the system may be disrupted.Interpretation of these results depends on age, time of day, recent illness, medications, and laboratory methods. Testosterone levels naturally decline with age, and acute stress or certain drugs can alter hormone levels. Assay variability between labs can also affect results, so context is essential for accurate assessment.
FAQs
It evaluates your hypothalamic–pituitary–testicular (HPT) axis to see if your body is making and signaling testosterone properly. Superpower tests your blood for Testosterone (total), Free Testosterone, Bioavailable Testosterone, Luteinizing Hormone (LH), and Follicle-Stimulating Hormone (FSH). Total and free/bioavailable T show androgen supply to tissues; LH and FSH show pituitary drive to the testes. Together they distinguish primary testicular dysfunction from central (pituitary/hypothalamic) causes.
It clarifies whether low androgen activity is present and where the problem lies. These hormones influence sexual function, fertility, muscle and bone maintenance, red blood cells, mood, and energy. Patterns across Testosterone, Free/Bioavailable T, LH, and FSH separate testicular failure from pituitary or hypothalamic suppression, guiding next steps and preventing missed diagnoses that affect long-term metabolic and skeletal health.
Yes. With Superpower, our team can organize a professional blood draw in your home. We’ll collect Testosterone, Free T, Bioavailable T, LH, and FSH in a single visit and handle logistics, transport, and lab processing so your results are consistent and comparable over time.
Start with a morning test and confirm on a separate morning if low or borderline. If results are abnormal or you’re monitoring a known issue, retest every 3–6 months until stable. Once stable, annual testing is reasonable, with earlier retesting if symptoms change or new medications that affect the HPT axis are started.
Timing matters: testosterone peaks in the morning and falls later in the day. Acute illness, poor sleep, caloric deficit, heavy endurance exercise, and stress can suppress GnRH/LH and lower T. SHBG shifts (aging, thyroid status, liver disease, obesity) alter Free/Bioavailable T. Medications like opioids, glucocorticoids, antiandrogens, and anabolic steroids can change levels. Assay variability and high-dose biotin can interfere with results.
Test in the morning (about 7–10 am) and use the same timing for repeats. Fasting is not required, but consistency helps. Avoid heavy exercise that morning and delay testing during acute illness. Hold high-dose biotin for 24–48 hours if you take it. Stay hydrated. If you use testosterone therapy, draw at the trough (just before your next dose) and note dose timing.
References
- Bhasin, S., Brito, J. P., Cunningham, G. R., Hayes, F. J., Hodis, H. N., Matsumoto, A. M., Snyder, P. J., Swerdloff, R. S., Wu, F. C., & Yialamas, M. A. (2018). Testosterone therapy in men with hypogonadism: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 103(5), 1715-1744. https://doi.org/10.1210/jc.2018-00229
- Basaria, S. (2014). Male hypogonadism. Lancet, 383(9924), 1250-1263. https://doi.org/10.1016/S0140-6736(13)61126-5
- Agarwal, A., Baskaran, S., Parekh, N., Cho, C. L., Henkel, R., Vij, S., Arafa, M., Panner Selvam, M. K., & Shah, R. (2021). Male infertility. Lancet, 397(10271), 319-333. https://doi.org/10.1016/S0140-6736(20)32667-2
- Tajar, A., Forti, G., O'Neill, T. W., Lee, D. M., Silman, A. J., Finn, J. D., Bartfai, G., Boonen, S., Casanueva, F. F., Giwercman, A., Han, T. S., Kula, K., Labrie, F., Lean, M. E. J., Pendleton, N., Punab, M., Vanderschueren, D., Huhtaniemi, I. T., & Wu, F. C. W. (2010). Characteristics of secondary, primary, and compensated hypogonadism in aging men: Evidence from the European Male Ageing Study. The Journal of Clinical Endocrinology & Metabolism, 95(4), 1810-1818. https://doi.org/10.1210/jc.2009-1796
- National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Hypogonadism. https://www.niddk.nih.gov/health-information/endocrine-diseases
.avif)
.svg)
.svg)
